期刊文献+

氧化三甲胺与心血管疾病研究进展 被引量:1

Advances in research on trimethylamine oxide with cardiovascular disease
原文传递
导出
摘要 近些年来,在控制传统危险因素的基础上中国居民心脑血管疾病的患病率与病死率仍处于上升阶段,因此探究新的心脑血管疾病影响因素尤其分子生物学标志物已成为研究热点。有研究表明肠道菌群代谢物氧化三甲胺的血浆水平升高具有促进心脑血管疾病发生与发展的作用。在高血压、冠心病、心衰、脑卒中患者中血浆氧化三甲胺水平明显升高,且对心脑血管疾病患者发生不良事件有预测价值。其主要致病机制为:促进动脉粥样硬化的发生发展,促进血栓形成。目前对于氧化三甲胺的研究主要局限于动物和特殊人群(患心脑血管疾病患者)中,未来应扩大研究对象在多中心、一般人群中研究验证。 In recent years,based on the control of traditional risk factors,the prevalence and mortality of cardiovascular diseases in Chinese residents are still in the rising stage,so the study of new cardiovascular disease factors,especially molecular biology markers has become a hot topic.Studies have shown that intestinal microbial metabolite oxidation of trimethylamine plasma levels have increased the development of the cardiovascular disease.In patients with hypertension,coronary heart disease,heart failure,stroke,plasma levels of trimethylamine were significantly increased,and cardiovascular disease in patients with adverse events have predictive value.The main pathogenesis is to promote the occurrence and development of atherosclerosis and promote thrombosis.At present,the study of trimethylamine is mainly confined to animals and special populations(patients suffering from cardiovascular and cerebrovascular diseases).The future should be expanded in the multi-center,the general population in the study and verification.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2017年第11期1120-1123,共4页 Journal of Clinical Cardiology
基金 辽宁省自然科学基金项目(No:20170541048) 国家自然基金项目(No:81302495)
关键词 氧化三甲胺 心血管疾病 动脉粥样硬化 血栓 trimethylamine oxide cardiovascular disease atherosclerosism thrombus
  • 相关文献

参考文献2

二级参考文献56

  • 1王芳,房建伟,王泽宇,斗章.高脂血症大鼠肠道菌群变化的实验研究[J].黑龙江医药科学,2005,28(4):52-53. 被引量:31
  • 2Hattori M, Taylor TD. The human intestinal microbiome: a new frontier of human biology [J]. DNA Res, 2009, 16(1 ) : 1-12.
  • 3Hao WL, Lee YK. Microflora of the gastrointestinal tract: a review [J]. Methods Mol Biol, 2004, 268: 491-502.
  • 4Wolever TM, Brighenti F, Royall D, et al. Effect of rectal infusion of short chain fatty acids in human subjects[ J]. Am J Gastroenter, 1989, 84(9): 102%1033.
  • 5Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota meta- bolic interactions[J]. Science, 2012, 336(6086) : 1262-1267.
  • 6Broxmeyer L. Heart disease: the greatest 'risk ' factor of them all [J]. Medical Hypotheses, 2004, 62(5) : 773-779.
  • 7Grill JP, Cayuela C, Antoine JM, et al. Effects of Lactobacillus amylovorus and Bifidobacterium breve on cholesterol [ J ]. Lett Appl Microbiol 2000, 31(2) : 154-156.
  • 8Hayashi H, Takahashi R, Nishi T, et al. Molecular analysis of jeju- nal, ileal, caecal and recto-sigmoidal human colonic microbiota using 16S rRNA gene libraries and terminal restriction fragment length poly- morphism[J].Med Microbiol, 2005, 54(11): 1093-1101.
  • 9Martinez I, Wallace G, Zhang C, et al. Diet-induced metabolic improvements in a hamster model of hypercholesterolemia are strongly linked to alterations of the gut microbiota [ J ]. Appl Envi-ron Microbiol 2009, 75 (12) : 4175-4184.
  • 10Stancu CS, Sanda GM, Deleanu M, et al. Probiotics determine hypolipidemic and antioxidant effects in hyperlipidemic hamsters [J].Mol Nutr Food Res, 2013, 58(3): 559-568.

共引文献62

同被引文献2

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部